David Y. Light

David Y. Light

Auto-generated profile, based on publicly available information

David Y. Light

Valisure, New Haven, Connecticut; Long Island University, Brooklyn, New York

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KKKaury Kucera
Kaury Kucera
NZNicola Zenzola
Nicola Zenzola
AHAmber Hudspeth
Amber Hudspeth
MDMara Dubnicka
Mara Dubnicka
WHWolfgang Hinz
Wolfgang Hinz
DLDavid Y. Light
David Y. Light

14 May 2025 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
ANAditya Narayan
Aditya Narayan
BTBen Teasdale
Ben Teasdale
AHA.J. Hudspeth
A.J. Hudspeth
DLDavid Y. Light
David Y. Light
JNJill K. Nailor
Jill K. Nailor
KSKevin Schulman
Kevin Schulman

19 February 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KKKaury Kucera
Kaury Kucera
Christopher G BunickChristopher G Bunick
Christopher G Bunick
DLDavid Y. Light
David Y. Light

29 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
VSVictor Suarez
Victor Suarez
CBCarl Bazil
Carl Bazil
CBChristopher Bunick
Christopher Bunick
PBPeter C. Butler
Peter C. Butler
ACAdam Clark-Joseph
Adam Clark-Joseph
KSKevin Schulman
Kevin Schulman
Objective: Conservatively quantify the public health and economic damages of low-quality generic drugs on chronic disease management in the United States based on available studies, and review health system solutions to avoid low-quality and incentivize high-quality generics. Data Sources: Generic drug quality is an evolving but sparse field of research; therefore, the expertise of 21 experts with experience in the field were relied upon to identify meaningful areas of existing research within chronic disease, where medication issues are expected to be most pronounced due to longevity and persistence of treatment. Four diseases (epilepsy, multiple sclerosis, atherosclerosis, and hypertension) were chosen by the group due to the relative abundance of informative studies and the diversity of the diseases. A chronological review of published health system solutions was also performed. Data Synthesis / Results: Extrapolating from studies in these four chronic diseases and focusing on the most directly observable 10% low-quality generic drugs, we conservatively estimate the 2024 economic burden of this low-quality subset of generic drugs at $18.4 billion growing to $238 billion over the next 10 years if not addressed, largely due to many thousands of avoidable serious adverse events like disease relapse and hospitalizations. Potential solutions are discussed that may enable a market correction to avoid the low-quality generic drugs and incentivize continuous product improvement. Conclusion and Relevance: This novel review represents the first broad population analysis of the substantial economic and public health impact from low-quality generic drugs and synthesizes modern approaches to addressing this largely underappreciated issue. Real-world approaches are reviewed where pharmacy practice can be modified to help ensure only the highest-quality generics are dispensed to patients to improve outcomes and reduce waste.

6 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
DODarin T. Okuda
Darin T. Okuda
IHIsabella J. Huddleston
Isabella J. Huddleston
MMMorgan C. McCreary
Morgan C. McCreary
KBKaty W. Burgess
Katy W. Burgess
CWCrystal M. Wright
Crystal M. Wright
TPTom G. Punnen
Tom G. Punnen